Abstract
Patient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs and survival in patients with metastatic Renal Cell Carcinoma (mRCC) in a real world setting. A retrospective analysis was performed using IQVIA real world oncology cross-sectional survey data, a retrospective treatment database collecting anonymized patient-level data in Europe. Data on treatment naïve patients with mRCC who received a first-line targeted therapy in France were extracted for the period 2005-2015. Descriptive analyses were performed on treatment patterns, patient characteristics and safety profiles. Progression Free Survival (PFS) was determined using Kaplan-Meier survival analysis. One thousand three hundred thirty-one patients with mRCC who received a first-line targeted therapy were included. The male/female sex ratio was 2.5 and 66% of patients were aged > 60 years. 83% of patients had clear cell adenocarcinoma. 83% of patients underwent a surgical procedure, 10% had radiotherapy. In patients who received a first-line targeted therapy, 73% received sunitinib. The mean time from diagnosis to first-line...Continue Reading
References
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Sep 25, 2007·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Louis P GarrisonC Daniel Mullins
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Jul 21, 2009·The Lancet Oncology·Martin E GoreRonald Bukowski
Oct 30, 2009·BJU International·Toni K ChoueiriWilliam K Oh
Feb 18, 2011·American Journal of Hematology·Daniela ZackovaJiri Mayer
Jul 17, 2013·Clinical Genitourinary Cancer·Michael R HarrisonAmy P Abernethy
Aug 24, 2013·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
May 21, 2014·European Urology·Laurence AlbigesAxel Bex
Jul 2, 2014·Current Medical Research and Opinion·Eric JonaschNicholas J Vogelzang
Aug 29, 2014·Clinical Genitourinary Cancer·Ian D SchnadigNicholas J Vogelzang
Nov 11, 2014·Current Medical Research and Opinion·L BenjaminC Ricarte
Dec 3, 2014·Clinical Genitourinary Cancer·Daniel M GeynismanYa-Chen Tina Shih
Jan 27, 2015·European Urology·Borje LjungbergAxel Bex
Jul 25, 2015·BJU International·Daphne DayBen Tran
Sep 18, 2015·Frontiers in Oncology·Miriam Argyropulo-PalmerDavid Montgomery
Oct 23, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J WagstaffS Buchan
Sep 21, 2016·PloS One·Rana MarounIsabelle Durand-Zaleski
Dec 25, 2016·The Breast : Official Journal of the European Society of Mastology·Paolo MarchettiJan Lewis
Citations
Nov 24, 2018·PharmacoEconomics·Chun-Ru ChienYa-Chen Tina Shih
Aug 6, 2019·Cancer·Sean KhozinAmy P Abernethy
Sep 5, 2019·Future Oncology·Sreeram V RamagopalanAndrew Cox
Mar 12, 2020·JCO Oncology Practice·Pinkie ChambersIan C K Wong
Jan 20, 2021·Future Oncology·George KafatosJörg Trojan
Sep 19, 2019·European Urology Focus·Sabrina H RossiEdward C F Wilson
Jun 25, 2021·Journal of Managed Care & Specialty Pharmacy·Thomas E HutsonAbhijeet Bhanegaonkar